Updated: BUPA plans long-term stay in India, targets top-three position
This article was originally published in Clinica
Executive Summary
One new private scheme due to be launched in 12-15 months' time is a joint venture between the UK's Bupa and India's Max India. Bupa will be the first outside entrant into the Indian market. Girija Shettar spoke to Bupa spokesman Kevin Mochrie about the initiative.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.